Your browser doesn't support javascript.
loading
Quality Tolerance Limits: A General Guidance for Parameter Selection and Threshold Setting.
Keller, Annett; van Borrendam, Nathalie; Benner, Patrice; Gilbert, Steven; Saino, Stefano; Jendrasek, Debra; Young, Steve; Muli, Marcus; Wang, Jim; Kozinska, Marta; Liu, Jun.
Afiliação
  • Keller A; Global Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH &Co. KG, Binger Strasse 173, 55216, Ingelheim, Germany. annett.keller@boehringer-ingelheim.com.
  • van Borrendam N; Integrated Data Analytics and Reporting, Janssen Research and Development, Graaf Engelbertlaan 75, 4837DS, Breda, Netherlands.
  • Benner P; Global Data Management and Standards, Merck & Co., Inc, 770 Sumneytown Pike, West Point, PA, 19486, USA.
  • Gilbert S; Statistical Research and Innovation, Pfizer, 100 Cambridge Park Drive, Cambridge, MA, 02140, USA.
  • Saino S; Risk Evaluation and Adaptive Integrated Monitoring, MSD, V. F.lli Cervi, Palazzo Canova, 20090, Segrate, Milan, Italy.
  • Jendrasek D; Risk Based Quality Management, Daiichi Sankyo, 211 Mount Airy Rd, Basking Ridge, NJ, 07920, USA.
  • Young S; Research, Cluepoints, 1000 Continental Drive, Suite 240, King of Prussia, PA, 19406, USA.
  • Muli M; Biostatistics and Research Decision Sciences, Merck & Co., Inc, 351 N. Sumneytown Pike, North Wales, PA, 19454, USA.
  • Wang J; Statistics & Decision Sciences, Janssen Research and Development, 920 Route 202, Raritan, NJ, 08869, USA.
  • Kozinska M; Centralized Monitoring, BioPharmaceuticals Clinical Operations, R&D, AstraZeneca, Postepu 14, 02-676, Warsaw, Poland.
  • Liu J; Centralized Monitoring, Astellas, 1 Astellas Way, Northbrook, IL, 60062, USA.
Ther Innov Regul Sci ; 58(3): 423-430, 2024 May.
Article em En | MEDLINE | ID: mdl-38321191
ABSTRACT
The past years have sharpened the industry's understanding of a Quality by Design (QbD) approach toward clinical trials. Using QbD encourages designing quality into a trial during the planning phase. The identification of Critical to Quality (CtQs) factors and specifically Critical Data and Processes (CD&Ps) is key to such a risk-based monitoring approach. A variable that allows monitoring the evolution of risk regarding the CD&Ps is called a Quality Tolerance Limit (QTL) parameter. These parameters are linked to the scientific question(s) of a trial and may identify the issues that can jeopardize the integrity of trial endpoints. This paper focuses on defining what QTL parameters are and providing general guidance on setting thresholds for these parameters allowing for the derivation of an acceptable range of the risk.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Ther Innov Regul Sci / Ther. innov. regul. sci. (Online) / Therapeutic innovation & regulatory science (Online) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos como Assunto Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Ther Innov Regul Sci / Ther. innov. regul. sci. (Online) / Therapeutic innovation & regulatory science (Online) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha